Levetiracetam Tablet, Film Coated
Product Images NDC 50090-7774

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 50090-7774). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label Image (Lbl500907774)

Label Image (Lbl500907774)
Levetiracetam 250 mg film-coated tablets in a package label from A-S Medication Solutions. The label shows the NDC 50090-7774-0 and indicates the product contains 120 tablets. It specifies storage at 68 to 77 degrees Fahrenheit and includes dosage instructions to see the package insert. The label also features a barcode and lot number space.*
FDA Label Image

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)
Bar chart titled "Responder Rate (≥50% Reduction from Baseline) in Study 1" presenting the percentage of patients achieving at least 50% reduction. It compares placebo (7.4%, N=95), Levetiracetam 1000 mg/day (37.1%, N=97), and Levetiracetam 3000 mg/day (39.6%, N=101). Statistical significance versus placebo is indicated by asterisks on the Levetiracetam bars.*
FDA Label Image

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)
A bar chart titled "Figure 2: Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A" showing the percentage of patients responding to treatment. The chart compares Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 2000 mg/day groups, with responder rates of 6.3%, 20.8%, and 35.2% respectively. An asterisk denotes statistically significant differences versus placebo.*
FDA Label Image

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)
A bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in Study 3' comparing the percentage of patients responding to Placebo (14.4%) versus Levetiracetam 3000 mg/day (39.4%). The x-axis shows treatment groups, and the y-axis shows percentage of patients from 0% to 45%. A note indicates statistical significance versus placebo marked by an asterisk.*
FDA Label Image

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)
A bar chart titled 'Responder Rate (≥ 50% Reduction from Baseline) in Study 4' comparing placebo and Levetiracetam. The y-axis shows percentage of patients from 0% to 45%. The placebo group (N=97) has a responder rate of 19.6%, while the Levetiracetam group (N=101) has a higher responder rate of 44.6%, marked as statistically significant versus placebo.*
FDA Label Image

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)
A bar graph displaying the responder rate for patients aged 1 month to less than 4 years achieving 50% or more reduction from baseline in Study 5. The graph compares placebo (19.6% responders, N=51) versus levetiracetam (43.1% responders, N=58), indicating a statistically significant difference favoring levetiracetam.*
FDA Label Image

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)
A bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in PGTC Seizure Frequency per Week in Study 7' comparing placebo and Levetiracetam. The vertical axis shows the percentage of patients from 0% to 100%. The placebo group (N=84) shows a 45.2% responder rate, while the Levetiracetam group (N=79) shows a higher responder rate of 72.2%, marked as statistically significant versus placebo.*
FDA Label Image

Chemical Structure (Levetiracetam Str)

Chemical Structure (Levetiracetam Str)
Chemical structure of Levetiracetam, showing a pyrrolidone ring attached to an ethyl group, a hydrogen atom, and an amide group (CONH2) bound to a central carbon.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.